Symbol | Exchange | Currency |
|---|
Shares in Clinigen Group PLC (LON: CLIN) are heading for their worst day on record. The pharmaceutical firm has lost a quarter of its value after it said the fallout from COVID-19...
Sept 17 (Reuters) - Britain's FTSE 100 (.FTSE) index is seen opening 34 points lower at 6,044 on Thursday, according to financial bookmakers, with futures (FFIc1) seen down 1%...
LONDON (Reuters) - Britain's Clinigen Group (L:CLINC) said on Tuesday it would buy Link Healthcare, a specialist pharma company focussed on markets in Asia, Africa and...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Neutral | Buy | Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
| Summary | Strong Sell | Buy | Strong Buy | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 18.40 | 18.50 | 18.30 | -0.350 | -1.89% | 9.05M | London | |||
| 315.75 | 317.45 | 313.40 | +4.10 | +1.32% | 18.95M | London | |||
| 167.12 | 168.54 | 165.62 | +1.80 | +1.09% | 18.53M | London | |||
| 118.84 | 121.12 | 118.04 | +2.80 | +2.41% | 93.01M | London | |||
| 15.73 | 16.14 | 15.28 | -0.09 | -0.57% | 154.03K | London | |||
| 143.20 | 143.50 | 138.40 | +1.30 | +0.92% | 914.69K | London | |||
| 95.63 | 98.83 | 95.33 | +0.35 | +0.37% | 23.87M | London | |||
| 36.69 | 37.09 | 36.00 | +0.76 | +2.12% | 6.38M | London | |||
| 760.00 | 768.00 | 757.00 | +1.00 | +0.13% | 47.29K | London | |||
| 116.20 | 116.60 | 116.20 | 0.00 | 0.00% | 0.00 | London | |||
| 482.40 | 482.50 | 476.10 | 0.00 | 0.00% | 0.00 | London | |||
| 50.00 | 50.40 | 49.55 | -0.20 | -0.40% | 398.94K | London | |||
| 1,569.00 | 1,572.50 | 1,547.50 | +25.00 | +1.62% | 933.10K | London | |||
| 417.60 | 418.20 | 408.60 | +9.20 | +2.25% | 1.05M | London | |||
| 152.80 | 159.90 | 151.90 | +0.30 | +0.20% | 522.66K | London |
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.